Download full-text PDF |
Source |
---|
Reprod Health
December 2024
UNDP‑UNFPA‑UNICEF‑WHO‑World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), Department of Sexual and Reproductive Health and Research, World Health Organization, 20 Avenue Appia, 1211, Geneva, Switzerland.
Background: The use of medical abortion using either a combination of mifepristone and misoprostol, or misoprostol alone has contributed to increased safety and decreased mortality and morbidity. The availability of quality medical abortion medicines is an essential component in the provision of quality abortion care. Understanding the factors that influence the availability of medical abortion medicines is important to help in-country policymakers, program planners, and providers improve availability and use of medical abortion.
View Article and Find Full Text PDFLancet Glob Health
January 2025
Médecins Sans Frontières Access Campaign, Geneva, Switzerland.
BMC Glob Public Health
July 2024
Department of Population and Public Health Sciences, Keck School of Medicine of University of Southern California, 1845 N Soto, Los Angeles, CA, 90033, USA.
Clin Transl Sci
September 2024
Botswana-University of Pennsylvania Partnership, Gaborone, Botswana.
Cancer
December 2024
Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!